At 3.5% CAGR, the MEA Epirubicin Market is projected to be worth US$ 13,896.58 thousand by 2028, says Business Market Insights           

According to Business Market Insights’ research, the MEA epirubicin market was valued at US$ 11,319.57 thousand in 2022 and is expected to reach US$ 13,896.58 thousand by 2028, registering an annual growth rate of 3.5% from 2022 to 2028. Increasing awareness regarding cancer and increase in number of cancer research programs are the critical factors attributed to the market expansion.          

Cancer awareness is the key to early detection and better wellbeing. Cancer is quite common in both developing and developed countries. A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization on March 8, 2021, to reduce breast cancer mortality by 2.5% annually until 2040. This initiative was presented to the cancer community on International Women's Day by the WHO in an advocacy event, "Hearing the call of women with breast cancer." The WHO Global Initiative for Childhood Cancer was launched in September 2018. The goal of the initiative is to achieve a 60% reduce in suffering of all children with cancer by 2030. WHO develops strategic action plans, led by governments and supported by individuals and groups across sectors for achieving the goals. World Cancer Day held every February 4, is the uniting initiative led by the Union for International Cancer Control (UICC). Created in 2000, World Cancer Day has grown into a positive movement for everyone everywhere to unite under one voice to face one of the greatest challenges in history. They focus on raising worldwide awareness; improving education; catalyzing personal, collective, and government action; and working together to prevent cancer deaths. Therefore, the increasing cancer awareness by various initiatives is driving the epirubicin market across the region.

On the contrary, elevated risk of adverse effects due to epirubicin hurdles the growth of MEA epirubicin market.    

• Based on dosage, the MEA epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held 39.3% market share in 2022, amassing US$ 4,450.14 thousand. It is projected to garner US$ 5,542.76 thousand by 2028 to expand at 3.7% CAGR during 2022–2028.        
• Based on application, the MEA epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held 72.3% market share in 2022, amassing US$ 8,182.34 thousand. It is projected to garner US$ 10,118.79 thousand by 2028 to expand at 3.6% CAGR during 2022–2028.       
• Based on distribution channel, the MEA epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 66.2% market share in 2022, amassing US$ 7,495.61 thousand. It is projected to garner US$ 9,293.47 thousand by 2028 to expand at 3.6% CAGR during 2022–2028.           
• Based on country, the MEA epirubicin market has been categorized into the UAE, Saudi Arabia, South Africa, and rest of MEA. Our regional analysis states that South Africa captured 36.8% market share in 2022. It was assessed at US$ 4,166.66 thousand in 2022 and is likely to hit US$ 5,262.56 thousand by 2028, exhibiting a CAGR of 4.0% during the forecast period.             

Key players dominating the MEA epirubicin market are Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. among others.                  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com